Rogaratinib is primarily investigated for its potential in treating cancers, particularly those driven by fibroblast growth factor receptor (FGFR) alterations. It is being studied in clinical trials for its efficacy in targeting FGFR1-4, which are often overexpressed or mutated in various cancers, including bladder, lung, and breast cancers. By inhibiting these receptors, Rogaratinib aims to disrupt cancer cell growth and survival. Its application is especially promising in patients with FGFR-positive tumors, offering a targeted therapy approach that could improve outcomes compared to traditional treatments. Research is ongoing to determine its full therapeutic potential and safety profile.